North Dakota Secures $27.8 Million Settlement in Opioid Litigation
The state of North Dakota has finalized a $27.8 million settlement with McKinsey & Company, resolving allegations that the global consulting firm contributed to the opioid epidemic through its marketing advisory services. The agreement, facilitated by legal counsel from Greenberg Traurig, LLP, directs funds toward state-led opioid abatement, treatment, and recovery programs.
How the Settlement Was Reached
The North Dakota Attorney General’s office led the litigation against McKinsey, asserting that the firm’s consulting work for major opioid manufacturers—including Purdue Pharma—helped accelerate the crisis. According to the North Dakota Office of Attorney General, the firm provided strategic advice that encouraged aggressive marketing tactics for prescription painkillers, even as addiction rates climbed nationwide. McKinsey reached the multi-state agreement in 2021 to resolve investigations into its role in the crisis without admitting liability.
Where the Funding Goes
The $27.8 million is earmarked for the North Dakota Department of Health and Human Services to expand access to addiction treatment and support services. This settlement is part of a broader national trend where states are recouping costs from entities involved in the opioid supply chain. Unlike previous settlements that focused on manufacturers or distributors, this agreement specifically targets the consulting sector’s role in shaping corporate strategy during the height of the epidemic.
Comparison: McKinsey Settlement vs. National Opioid Settlements
| Entity | Scope | Primary Focus |
|---|---|---|
| McKinsey & Company | $573 Million (Total U.S. states) | Consulting/Marketing Advice |
| Major Distributors | $26 Billion (National) | Supply Chain/Distribution |
Why This Case Matters
This litigation establishes a precedent for holding professional service firms accountable for the outcomes of their corporate strategies. While many opioid cases focus on the direct sale of medication, the North Dakota settlement highlights the influence of third-party advisors. According to court filings summarized by the Greenberg Traurig legal team, the state argued that McKinsey’s data-driven strategies helped manufacturers target high-prescribing doctors, effectively fueling the over-prescription of opioids.
Frequently Asked Questions
- What does the settlement pay for? The funds are legally restricted to opioid abatement, including prevention, treatment, and recovery support.
- Did McKinsey admit wrongdoing? No. The settlement agreement explicitly states that the firm does not admit liability or wrongdoing.
- How is the money distributed? The funds are managed by the state and distributed to local health agencies and regional programs tasked with addressing substance abuse.
Future Outlook
The state continues to monitor the impact of the opioid epidemic through its opioid response portal. As funds are deployed, the focus shifts to long-term sustainability for community-based recovery centers. State officials maintain that these resources are critical for addressing the ongoing challenges of fentanyl and synthetic opioid misuse in rural and urban North Dakota communities.